Eucrisa and Injection site reaction - a phase IV clinical study of FDA data

Summary:

Injection site reaction is reported as a side effect among people who take Eucrisa (crisaborole), especially for people who are female, 40-49 old, have been taking the drug for 1 - 2 years also take Dupixent, and have Dermatitis atopic.

The phase IV clinical study analyzes which people have Injection site reaction when taking Eucrisa. It is created by eHealthMe based on reports of 9,895 people who have side effects when taking Eucrisa from the FDA, and is updated regularly.

What is Eucrisa?

Eucrisa has active ingredients of crisaborole. eHealthMe is studying from 9,900 Eucrisa users. Check the latest studies of Eucrisa.

What is Injection site reaction?

Injection site reaction is found to be associated with 1,124 drugs and 1,075 conditions by eHealthMe. Check the latest studies of Injection site reaction.

On Jul, 26, 2026

9,895 people reported to have side effects when taking Eucrisa.
Among them, 40 people (0.4%) have Injection site reaction.

Could Eucrisa cause Injection site reaction?

Among these 40 people:

How long have people been on Eucrisa when they have Injection site reaction? *

What is the gender of people who have Injection site reaction when taking Eucrisa? *

female: 89.74 %
male: 10.26 %

What is the age of people who have Injection site reaction when taking Eucrisa? *

What are other drugs people take besides Eucrisa? *

What are other side effects people have besides Injection site reaction? *

Itching: 19 people, 47.50%
Rashes (redness): 19 people, 47.50%
Joint Pain: 13 people, 32.50%
Pain: 12 people, 30.00%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 11 people, 27.50%
Musculoskeletal Discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves): 11 people, 27.50%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 11 people, 27.50%
Nasopharyngitis (inflammation of the nasopharynx): 10 people, 25.00%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 10 people, 25.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 10 people, 25.00%

What are the existing conditions these people have? *

Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 23 people, 57.50%
Urinary Tract Infection: 10 people, 25.00%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 10 people, 25.00%
Cellulitis (infection under the skin): 10 people, 25.00%
Asthma: 3 people, 7.50%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 2.50%
Neurodermatitis (a skin disorder characterized by long lasting itching and scratching): 1 person, 2.50%
Impetigo (contagious skin infection): 1 person, 2.50%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 1 person, 2.50%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Eucrisa and have Injection site reaction?

- Check whether Injection site reaction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eucrisa:

Eucrisa (9,900 reports)

Browse all side effects of Eucrisa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site reaction:

Injection site reaction (1,125 drugs)

Browse all the conditions that are associated with Injection site reaction:

Injection site reaction (1,075 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on crisaborole (the active ingredients of Eucrisa) and Eucrisa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.